FALSE000111314800011131482023-09-122023-09-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 12, 2023
Infinity Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware000-3114133-0655706
(State or other jurisdiction
of incorporation)
(Commission File Number)(IRS Employer
Identification No.)
1100 Massachusetts Avenue, Floor 4, Cambridge, MA
02138
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 453-1000
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareINFINasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨
Item 3.01.     Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 12, 2023, Infinity Pharmaceuticals, Inc. (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, based on (i) the Company’s continued non-compliance with The Nasdaq Global Select Market’s requirement to maintain a minimum bid price of $1.00 per share under Listing Rule 5450(a)(1) and (ii) the Company’s failure to provide adequate detail regarding its compliance plan to justify the Nasdaq Hearings Panel (the “Panel”) granting an exception to the continued listing standards, the Company’s common stock will be suspended from trading on Nasdaq at the open of business on September 14, 2023 unless the Company requests a review of this decision. The Company does not plan to request a review of the Panel’s decision.
The Company’s common stock may be eligible to be quoted on the Pink Open Market operated by the OTC Markets Group Inc. if a market maker sponsors the security and complies with Rule 15c2-11 under the Securities Exchange Act of 1934, as amended, but the Company can provide no assurances that a public market for trading the Company’s common stock will exist after the expected suspension of trading on September 14, 2023.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INFINITY PHARMACEUTICALS, INC.
Date: September 13, 2023By:/s/ Seth A. Tasker
Chief Executive Officer



v3.23.2
Cover
Sep. 12, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 12, 2023
Entity Registrant Name Infinity Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 000-31141
Entity Tax Identification Number 33-0655706
Entity Address, Address Line One 1100 Massachusetts Avenue
Entity Address, Address Line Two Floor 4
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02138
City Area Code 617
Local Phone Number 453-1000Not applicable(Former name or former address, if changed since last report)
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol INFI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001113148

Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Infinity Pharmaceuticals Charts.
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Infinity Pharmaceuticals Charts.